Summary by Moomoo AI
C4 Therapeutics, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are not preliminary and that no filing fee is required. The proxy materials are related to the company's upcoming decisions that require shareholder votes, although the specific resolutions or proposals are not detailed in this announcement. The filing was made by C4 Therapeutics, Inc. itself, rather than by an external party.